Clinical Trial Update: Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the corrected QT interval effects of trastuzumab emtansine (T-DM1) and the safety/tolerability of combining T-DM1 with pertuzumab in pa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Kadcyla (ado-trastuzumab emtansine)
• Perjeta (pertuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Metastatic Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-05-01